Cellvie
Cellvie: Developing cell-derived medicines by leveraging the therapeutic potential of mitochondria to treat ischemia-reperfusion injuries.
Founded
2018Cellvie: Developing cell-derived medicines by leveraging the therapeutic potential of mitochondria to treat ischemia-reperfusion injuries.
Cellvie was founded with the core mission of developing cell-derived medicines by leveraging the therapeutic potential of mitochondria to treat ischemia-reperfusion injuries. The company focuses on pioneering Therapeutic Mitochondria Transplantation, a novel treatment approach aimed at enhancing cellular energy metabolism. By harnessing the powerhouses of the cell, Cellvie aims to restore and save cellular functions, targeting conditions that benefit from improved mitochondrial performance.
Notable affiliated individuals and investors include experts in biotechnology and healthcare, though specific names are not provided. Key achievements for Cellvie include advancing the understanding and application of mitochondria in therapeutic contexts, potentially revolutionizing treatments for energy metabolism-related conditions. The overall impact of Cellvie's work lies in its innovative approach to medicine, which could significantly improve outcomes for patients suffering from various cellular energy deficiencies.
Companies similar to Cellvie include Mitosense, Imel Biotherapeutics, Capacity Bio and Mitogenetics.
Cellvie was founded in 2018.
Cellvie's headquarters is located in Houston, TX, US.
Cellvie's most recent funding round was for $5.5M (USD) in February 2023.
As of Feb 6, 2023, Cellvie has disclosed funding of $10.5M (USD). Undisclosed round amounts are excluded.
Cellvie has 9 employees as of Feb 4, 2024.
Mitogenetics
mitogenetics.com
